Prescription under medical supervision

Therapeutic action

– Anthelminthic (antifilarial)


– Lymphatic filariasis

Forms and strengths

– 100 mg breakable tablet


– Child under 10 years: 0.5 mg/kg on D1, then increase the dose gradually over 3 days to 1 mg/kg 3 times daily
– Child over 10 years and adult: 1 mg/kg on D1, then increase the dose gradually over 3 days to 2 mg/kg 3 times daily


 W. bancrofti: 12 days; B. malayiB. timori: 6 to 12 days

Contra-indications, adverse effects, precautions

– Do not administer to patients with onchocerciasis or heavy Loa loa microfilareamia; to infants, elderly patients and patients with heart or renal diseases.
– Do not administer during acute attacks (risk of severe reactions).
– Administer with caution in patients with history of seizures.
– May cause:
• nausea, vomiting, headache, dizziness, drowsiness, fever, joint pain, urticaria, transient haematuria, subcutaneous nodules, lymphangitis, localized oedema;
• in patients with associated onchocerciasis: severe ocular damages (optic nerve lesions, retinal lesions);
• in patients with associated loiasis: encephalitis (potentially fatal) if Loa loa microfilaraemia is high.
– Reduce dosage in patients with renal impairment.
– PregnancyCONTRA-INDICATED (treatment may be deferred until after delivery)
– Breast-feeding: not recommended


– In countries with a national programme for the elimination of bancroftian filariasis, the combination diethylcarbamazine + albendazole is administered as a single annual dose for 4 to 6 years. This regimen is only suitable for countries that are free from Onchocerca volvulus and/or Loa loa.
– Diethylcarbamazine is included in the WHO complementary list of essential medicines.
– Storage: between 15 °C and 25 °C -